Filing Details

Accession Number:
0001104659-22-012868
Form Type:
4
Zero Holdings:
No
Publication Time:
2022-02-07 17:15:57
Reporting Period:
2022-02-03
Accepted Time:
2022-02-07 17:15:57
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1722964 Y-Mabs Therapeutics Inc. YMAB Pharmaceutical Preparations (2834) 474619612
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1753224 Thomas Gad C/O Y-Mabs Therapeutics, Inc.
230 Park Avenue, Suite 3350
New York NY 10169
See Remarks Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2022-02-03 35,060 $7.90 947,306 No 4 S Indirect By GAD Enterprises LLC
Common Stock Disposition 2022-02-04 101,104 $7.70 846,202 No 4 S Indirect By GAD Enterprises LLC
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By GAD Enterprises LLC
No 4 S Indirect By GAD Enterprises LLC
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 60,000 Indirect By Children
Common Stock 50,000 Direct
Footnotes
  1. Represents shares sold by lender pursuant to a forced sale of common stock pledged to secure a margin loan pursuant to an agreement with the lender following a margin call on the common stocksecuring the margin loan.
  2. This transaction was executed in multiple trades at prices ranging from $7.8100 to $8.1100. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. Reporting Person is sole member of GAD Enterprises, LLC and the sole member and manager of GAD Management, LLC, the manager of GAD Enterprises, LLC, and as such Reporting Person has sole voting and dispositive power with respect to such shares.
  4. This transaction was executed in multiple trades at prices ranging from $7.4200 to $8.000. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. Represents shares owned by Reporting Person's children who are deemed to share Reporting Person's household.